Provided by Tiger Trade Technology Pte. Ltd.

Novartis AG

138.70
+0.08000.06%
Post-market: 139.200.5000+0.36%19:46 EDT
Volume:1.89M
Turnover:263.70M
Market Cap:264.64B
PE:20.97
High:141.46
Open:140.58
Low:138.28
Close:138.62
52wk High:170.46
52wk Low:121.57
Shares:1.91B
Float Shares:1.85B
Volume Ratio:0.75
T/O Rate:0.10%
Dividend:4.67
Dividend Rate:3.36%
EPS(TTM):6.61
EPS(LYR):7.15
ROE:30.35%
ROA:10.25%
PB:6.37
PE(LYR):19.40

Loading ...

Novartis is Having a Very Bad September-and More Pain Could be on the Way

Dow Jones
·
Sep 08

Update: US Equity Futures Mostly Lower as Traders Assess Rising Oil, Canadian Retaliatory Tariffs

MT Newswires Live
·
Sep 08

【US Pre-Market】Middle East Energy Risks Escalate, Brent Crude Nears $100, Oil and Gas Stocks Rise; Novartis Plunges 13%

TradingKey
·
Sep 08

Monte Rosa Therapeutics to receive $50M milestone payment from Novartis

TIPRANKS
·
Sep 08

Beneath the Surface, the Next Market Leaders are Getting Ready to Break Out, Says Morgan Stanley

Dow Jones
·
Sep 08

Novartis Dealmaking Serves as Cautionary Tale for Pharma M&A

Dow Jones
·
Sep 08

Swiss Pharma Giant Hit by Triple Trial Setbacks, Shares Plunge Nearly 10% in Steepest One-Day Drop Since 2020

Deep News
·
Sep 08

Stock Market Today: S&P 500, Dow Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction — ASML, NVS, CASY in Focus

Benzinga Earnings
·
Sep 08

Novartis India Hits Record High on Retina Drugs Distribution Deal, Pfizer Brand Acquisition

Reuters
·
Sep 08

Stocks to Watch: Amgen, Nike, Bloom Energy

Dow Jones
·
Sep 08

Novartis Stock (NVS) Sinks on Another Setback, Muscle-Wasting Disorder Drug Disappoints

TIPRANKS
·
Sep 08

Pharmaceutical Giant's Shares Plunge Nearly 10% Following Triple Clinical Trial Setbacks

Deep News
·
Sep 08

Novartis Might Need More Deals to Deliver Growth Ambitions

Dow Jones
·
Sep 08

Why the Dow is Being Dragged Down by a Swiss Company's Bad News

Dow Jones
·
Sep 08

Novartis AG Falls 13% in Pre-Market Trading, DM1 Drug Phase III Clinical Trial Fails to Meet Primary Endpoint

Market Focus
·
Sep 08

Novartis's Latest Trial Setback Sinks Stock

Dow Jones
·
Sep 08

Novartis Genetic Muscle Disorder Drug Fails Phase 3 Trial; Shares Drop Pre-Bell

MT Newswires Live
·
Sep 08

The Inflammation Bet Unravels: Novo And Novartis Both Stumble In Cardiovascular

Bellwether Stocks Movement
·
Sep 08

United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday

Benzinga Earnings
·
Sep 08

Novartis's Latest Trial Failure is Second Pipeline Setback in a Row

Dow Jones
·
Sep 08